Antibiotic-associated diarrhea

CHOP Researchers Reveal How NSAIDs Worsen C. difficile Infections

Retrieved on: 
Wednesday, July 19, 2023
Infection, Clostridioides difficile infection, Medical laboratory, Diet, Bleeding, Cell death, CHOP, Mitochondrion, IBD, Epithelium, Enzyme, Naproxen, NSAID, Perforation, Philadelphia, Research, Antibiotic-associated diarrhea, Cell, Inflammation, Doctor of Philosophy, Aspirin, Assistant, Colon, Inflammatory bowel disease, Pain, Clostridioides difficile, HIV disease progression rates, Permeability, Patient, Pathology, Colorectal cancer, Nonsteroidal anti-inflammatory drug, DOI, Extrapyramidal system, Mouse, Indometacin, Mortality, Hospital, Ulcer, Death, COX, NIH, Virulence, Children's Hospital of Philadelphia, Pharmaceutical industry, Science Advances, Clostridioides, Child

PHILADELPHIA, July 19, 2023 /PRNewswire/ -- Why do nonsteroidal anti-inflammatory drugs (NSAIDs) exacerbate gastrointestinal infections by Clostridioides difficile, the leading cause of antibiotic-associated diarrhea worldwide? In a new paper published in Science Advances, researchers at Children's Hospital of Philadelphia (CHOP) have begun to answer that question, showing that NSAIDs disrupt the mitochondria of cells lining the colon, sensitizing them to damage by pathogenic toxins.

Key Points: 
  • However, researchers still know very little about how these factors impact the course of C. difficile infection.
  • Prior studies have shown that NSAIDs like indomethacin, aspirin, and naproxen negatively affect the gut, both in patients with C. difficile infection and other conditions like inflammatory bowel disease (IBD).
  • The researchers observed that both indomethacin and a C. difficile toxins increased epithelial cell barrier permeability and inflammatory cell death.
  • Surprisingly, the researchers found that NSAIDs exacerbate C. difficile infection independent of COX inhibition and instead through off-target effects on mitochondria.

Global Probiotics Dietary Supplements Market Report 2023: Sector is Expected to Reach $51.84 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 10, 2023
Food, Beverage, Other Health, Health, Retail, Fitness & Nutrition, Flintstones Chewable Vitamins, ADM, Skin, Enzyme, Probiotic, Diarrhea, Streptococcus thermophilus, Functional food, Urinary tract infection, Tablet, Human, Irritable bowel syndrome, Antibiotic-associated diarrhea, Research, USD, Incidence, Acquisition, Dietary supplement, Application, Immune system, Yogurt, Form, Lactobacillus, Powder, Capsule

The "Probiotics Dietary Supplements Market Size, Share & Trends Analysis Report By Form (Chewables & Gummies, Capsules, Powders, Tablets & Softgels), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Probiotics Dietary Supplements Market Size, Share & Trends Analysis Report By Form (Chewables & Gummies, Capsules, Powders, Tablets & Softgels), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global probiotics dietary supplements market size is expected to reach USD 51.84 billion by 2030, registering a CAGR of 14.1% over the forecast periods.
  • Probiotic dietary supplements have become increasingly popular in recent years, driven by a number of factors.
  • For instance, in November 2022, ADM acquired Deerland Probiotics & Enzymes, a manufacturer of dietary supplements utilizing probiotic, prebiotic, and enzyme technologies.

2023 Kappa Delta Ann Doner Vaughn Award Presented to Michelle Ghert, MD, FRCSC, and the PARITY Investigators for First-Ever International Multi-Center Randomized Controlled Trial in Orthopaedic Oncology

Retrieved on: 
Friday, February 10, 2023
Cefuroxime, Clostridioides, Caregiver, Christianity in Singapore, McMaster University, Journal, Infection, Bone, Pelvic floor dysfunction, American Medical Association, Korea Disease Control and Prevention Agency, The Journal of Bone and Joint Surgery, Antibiotic prophylaxis, Antibiotic-associated diarrhea, Clostridioides difficile, Medicine, Patient, Cancer, Cefazolin, Megacolon, Staphylococcus, Oncology, Kappa Delta, Biostatistics, Incidence, Database, Bone sarcoma, Research, RCT, Soft-tissue sarcoma, Tibia, Mortality, Amputation, Risk, FRCSC, CDC, Optimism, Staphylococcus aureus, Immune system, Femur, Survival, MD, SSI, Quality of life, Surgeon, Bone disease, Doctor of Philosophy, JAMA Oncology, Dentistry, Pharmaceutical industry

Their work resulted in the first-ever international, multi-center randomized controlled trial (RCT) in orthopaedic oncology as well as the largest collaborative effort in orthopaedic surgery with regards to the number of countries collaborating.

Key Points: 
  • Their work resulted in the first-ever international, multi-center randomized controlled trial (RCT) in orthopaedic oncology as well as the largest collaborative effort in orthopaedic surgery with regards to the number of countries collaborating.
  • "However, in orthopaedic oncology, where we treat rare diseases, it was a shift in our research paradigm.
  • I give a lot of credit to the first few clinical sites that joined the study as they took a leap of faith."
  • The PARITY investigators work resulted in 13 manuscripts published in peer-reviewed journals, including The Journal of the American Medical Association (Oncology).

Canadians suffering from diarrhea-predominant Irritable Bowel Syndrome (IBS-D) have a new clinically proven option approved by Health Canada

Retrieved on: 
Monday, March 9, 2020
Medical specialties, Medicine, Clinical medicine, RTT, Abdominal pain, Irritable bowel syndrome, Feces, Waterborne diseases, Antibiotic-associated diarrhea, Diarrhea, Probiotic, Clostridioides difficile

LAVAL, QC, March9, 2020 /CNW Telbec/ - Bio-K Plus International Inc. (Bio-K Plus) is pleased to announce the availability of Bio-K+ IBS Control a new, clinically proven probiotic for diarrhea-predominant Irritable Bowel Syndrome (IBS-D).

Key Points: 
  • LAVAL, QC, March9, 2020 /CNW Telbec/ - Bio-K Plus International Inc. (Bio-K Plus) is pleased to announce the availability of Bio-K+ IBS Control a new, clinically proven probiotic for diarrhea-predominant Irritable Bowel Syndrome (IBS-D).
  • However, Canadians suffering from IBS-D have limited options to help manage this challenging condition.
  • Bio-K Plus offers probiotics indicated to help prevent or manage serious health conditions such as antibiotic-associated diarrhea (AAD), Clostridium difficile-associated diarrhea (CDAD)and irritable bowel syndrome (IBS).
  • Its products are trusted by thousands of healthcare professionals and dispensed in over 200 hospitals throughout Canada and the United States.

Trans-Atlantic study finds promising results with Visbiome Vet, a high potency probiotic, in dogs with severe form of acute diarrhea

Retrieved on: 
Wednesday, December 12, 2018
Bacteria, Digestive system, Bacteriology, Probiotics, Lactobacillaceae, Gram-positive bacteria, Clostridium perfringens, Antibiotic-associated diarrhea, Lactobacillus casei

The study evaluated the impact of Visbiome Vet probiotic consumption on dogs with acute hemorrhagic diarrhea syndrome (AHDS).

Key Points: 
  • The study evaluated the impact of Visbiome Vet probiotic consumption on dogs with acute hemorrhagic diarrhea syndrome (AHDS).
  • The placebo-controlled, blinded trial found that dogs administered the probiotic experienced significantly faster clinical recovery over the 21 days of the trial.
  • Dogs in the treatment group also demonstrated higher concentrations of healthy microbes and significantly lower quantities of the pathogenic bacterium Clostridium perfringens.
  • Visbiome Vet is a high potency, eight-strain, probiotic, which has been the subject of numerous recent clinical publications in companion animals.

Rebiotix Microbiota Restoration Therapy™ Products, Microbiome Health Index™ to Take Center Stage at Digestive Disease Week 2018

Retrieved on: 
Monday, June 4, 2018
Bacteria, Clostridiaceae, Gram-positive bacteria, Diarrhea, C. Diff, Clostridium difficile, Clostridium, Infection, Breakthrough therapy, Fecal microbiota transplant, Antibiotic-associated diarrhea

Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff)infection.

Key Points: 
  • Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff)infection.
  • RBX2660 has been granted Fast Track status, Orphan Drug and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection.
  • In addition, Rebiotix is targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy platform.
  • Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women's health, and in specialty areas within gastroenterology and urology.